Quviviq

Chemical Namedaridorexant
Dosage FormTablets (oral; 25 mg, 50 mg)
Drug ClassOrexin receptor antagonists
SystemNervous
CompanyIdorsia Pharmaceuticals
Approval Year2022

Indication

  • For the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Document TitleYearSource
Quviviq (daridorexant) Prescribing Information.2022Idorsia Pharmaceuticals US Inc., Radnor, PA
Drug updated on 7/7/2023

More on this drug: Clinical Trials